Metastatic triple‐negative breast cancer: Established and emerging treatments

Metastatic triple‐negative breast cancer (mTNBC) patients tend to have a poor overall survival. The primary goals of treatment focus on palliation of symptoms and improvement in overall survival (OS). Single‐agent sequential chemotherapy with anthracycline or taxane has remained the cornerstone of t...

Full description

Saved in:
Bibliographic Details
Published inThe breast journal Vol. 26; no. 9; pp. 1793 - 1796
Main Authors Puri, Akshjot, Reddy, Tejaswini P., Patel, Tejal A., Chang, Jenny C.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.09.2020
Subjects
Adenosine
Adenosine diphosphate
advances
Anthracycline
Antibodies
Breast cancer
Chemotherapy
FDA approval
immunotherapy
Metastases
Metastasis
metastatic
Monoclonal antibodies
Mutation
Paclitaxel
Palliation
PARP inhibitors
PD-L1 protein
Poly(ADP-ribose) polymerase
Ribose
Survival
Targeted cancer therapy
Taxanes
TNBC
metastatic
TNBC
PARP inhibitors
advances
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Metastatic triple‐negative breast cancer (mTNBC) patients tend to have a poor overall survival. The primary goals of treatment focus on palliation of symptoms and improvement in overall survival (OS). Single‐agent sequential chemotherapy with anthracycline or taxane has remained the cornerstone of treatment for many years. The FDA has approved newer agents such as poly‐adenosine diphosphate‐ribose polymerase (PARP) inhibitors upfront in germline BRCA (gBRCA) 1/2 mutation carriers; atezolizumab and nab‐paclitaxel combination frontline in patients with PD‐L1 expression > 1%; and sacituzumab govitecan (IMMU‐132), an antibody‐drug conjugate in heavily pretreated mTNBC patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1075-122X
1524-4741
DOI:10.1111/tbj.13946